Medicine
Lemtrada 12 mg/1.2 mL injection
Lemtrada 12 mg/1.2 mL injection is a prescription medicine containing Alemtuzumab for intravenous use, marketed by Genzyme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store LEMTRADA vials at 2°C to 8°C (36°F to 46°F). Do not freeze or shake…
Key facts
- Active ingredient (INN)
- Alemtuzumab
- Brand
- Lemtrada
- Strength
- 12 mg/1.2 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 1.2 mL
- Marketing authorisation holder
- Genzyme
- Manufacturer
- Genzyme
- Origin register
- US FDA, United States
- Storage
- Store LEMTRADA vials at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Store in original carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XC04 Alemtuzumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 November 2014
- Identifiers
- RxCUI 1594658, 1594663DailyMed set ID 6236b0bc-82e9-4447-9a78-f57d94770269NDC 58468-0200Application BLA103948
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 1.2 mL in 1 vial, single-use | 58468-0200-1 | Genzyme | 18 November 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Alemtuzumab
Clinical summary
Alemtuzumab is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). It is available as injection for intravenous use. MedsAcross supplies Alemtuzumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AlemtuzumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Campath prescribing information (Genzyme) · U.S. National Library of Medicine, DailyMed
- Lemtrada: European public assessment report (EPAR) · European Medicines Agency
Need Lemtrada 12 mg/1.2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.